Westover Capital Advisors LLC Takes Position in Supernus Pharmaceuticals, Inc. $SUPN

Westover Capital Advisors LLC bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 31,939 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,587,000. Westover Capital Advisors LLC owned about 0.06% of Supernus Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of SUPN. Hantz Financial Services Inc. lifted its stake in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the last quarter. Torren Management LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $49,000. EverSource Wealth Advisors LLC bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $51,000. Smartleaf Asset Management LLC raised its position in Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $55,000.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $48.21 on Monday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $30.83 and a fifty-two week high of $59.68. The business’s 50 day moving average price is $49.99 and its two-hundred day moving average price is $49.64. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of -94.53, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57.

Analyst Ratings Changes

A number of research firms have commented on SUPN. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the transaction, the vice president owned 17,044 shares in the company, valued at approximately $856,972.32. This represents a 74.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Georges Gemayel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total value of $537,100.00. Following the transaction, the director owned 28,159 shares in the company, valued at $1,512,419.89. This trade represents a 26.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 116,406 shares of company stock worth $5,911,086 over the last quarter. Insiders own 8.80% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.